Figure 6

CPM treatments cause stage dependent effects on eye DV polarity. (A) Lateral views of heads of st. 33 embryos treated with ethanol (mock) or 100 μM CPM from the indicated stages and hybridized with probes for Pax2, Vax1b, Vax2 or Tbx3. Compared to controls, CPM-treated embryos show stage-dependent changes in gene expression domains along the anteroposterior (AP; Pax2, Vax1b) or the DV (Vax2, Tbx3) axes of the eye. Scale bar, 200 μm. (B) Quantification of the mean AP (Pax2, Vax1b) or DV (Vax2, Tbx3) width/height of gene expression domains, normalized to total width/height of the eye, in the eyes of embryos treated as in (A). The number of eyes analysed for each probe and treatment condition is indicated within the corresponding histogram bar. Error bars show standard deviations. *P < 0.05; ns, non-significant (P ≥ 0.05) according to two-tailed Student’s t-test. (C) Histological sections of eyes of st. 33 embryos treated with ethanol or CPM from st. 13 and hybridized with the indicated probes. CPM-treated eyes show a reduction of Pax2, Vax1b and Vax2 expression domains along the eye proximodistal axis. Yellow brackets highlight the proximodistal extent of the whole ventral eye region. Scale bar, 100 μm.